Ibrutinib Improves Outcomes in CLL/SLL

News
Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

This video examines a phase III trial of ibrutinib in combination with bendamustine and rituximab in patients with previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma.

In this video, Asher A. Chanan-Khan, MD, of the Mayo Clinic in Jacksonville, Florida, discusses a phase III trial of ibrutinib in combination with bendamustine and rituximab in patients with previously treated chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

The trial’s results (abstract LBA7005) were presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting held May 29–June 2 in Chicago.

Recent Videos
A phase 1/2 trial assessed the use of menin inhibitor DSP-5336 in patients with acute leukemia overexpressing HOXA9 and MEIS1.
A pooled analysis trial assessed the impact of acalabrutinib in patients with chronic lymphocytic leukemia across treatment lines.
Future meetings may address how immunotherapy, bispecific agents, and CAR T-cell therapies can further impact the AML treatment paradigm.
Treatment with revumenib appeared to demonstrate efficacy among patients with KMT2A-rearranged acute leukemia in the phase 2 AUGMENT-101 study.
Advocacy groups such as Cancer Support Community and the Leukemia & Lymphoma Society may help support patients with CML undergoing treatment.
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Data from the REVEAL study affirm elevated white blood cell counts and higher variant allele frequency as risk factors for progression in polycythemia vera.
Additional analyses of patient-reported outcomes and MRD status in the QuANTUM-First trial are also ongoing, says Harry P. Erba, MD, PhD.
Overall survival data with blinatumomab in the phase 3 E1910 study may be an “important development” in CD19-positive B-ALL.
Related Content
Following rare CRS and ICANS incidence following CAR T-cell therapy, investigators propose a reduced 2-week monitoring period with extensions as needed.

Flexible Monitoring for CAR T-Cell Therapy May Improve Treatment Access

Roman Fabbricatore
July 24th 2024
Article

Following rare CRS and ICANS incidence following CAR T-cell therapy, investigators propose a reduced 2-week monitoring period with extensions as needed.

Experts discuss updated findings presented at the 2024 EHA Congress in diseases such as mantle cell lymphoma and acute myeloid leukemia.

Ensuring Quality Outcomes in Hematologic Cancer Subgroups at EHA 2024

Manali Kamdar, MD;Michael Grunwald, MD;Harry P. Erba, MD, PhD
June 24th 2024
Podcast

Experts discuss updated findings presented at the 2024 EHA Congress in diseases such as mantle cell lymphoma and acute myeloid leukemia.

SLS009 is a highly selective CDK9 inhibitor that is being studied in an ongoing phase 1/2 trial for patients with hematologic malignancies.

FDA Grants SLS009 Rare Pediatric Disease Designation in Pediatric AML

Gina Mauro
July 21st 2024
Article

SLS009 is a highly selective CDK9 inhibitor that is being studied in an ongoing phase 1/2 trial for patients with hematologic malignancies.

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Applying Updated Breast Cancer Findings From ASCO to Clinical Practice

Neil M. Iyengar, MD;Paolo Tarantino, MD
June 17th 2024
Podcast

Neil M. Iyengar, MD, and Paolo Tarantino, MD, discuss updated data on agents such as T-DXd and abemaciclib in breast cancer presented at 2024 ASCO.

Data from a phase 1/2 trial support the potential clinical activity of DSP-5336 in patients with relapsed/refractory AML harboring a KMT2A rearrangement.

DSP-5336 Earns FDA Fast Track Status in R/R KMT2A+ Acute Myeloid Leukemia

Russ Conroy
July 16th 2024
Article

Data from a phase 1/2 trial support the potential clinical activity of DSP-5336 in patients with relapsed/refractory AML harboring a KMT2A rearrangement.

Investigators evaluated the impact of low-molecular weight heparin after the first 60 days of treatment as well as treatment overall.

Low-Molecular Weight Heparin Shows No VTE Reduction in Newly Diagnosed ALL

Gina Mauro
July 10th 2024
Article

Investigators evaluated the impact of low-molecular weight heparin after the first 60 days of treatment as well as treatment overall.